SB623 Joint Development and Licensing Agreement with Dainippon Sumitomo Pharma
First written in FY2017-Q1. 10 of 12 entries say "Restated". Latest entry: FY2020-Q3.
1 other company's latest entry also says "Dropped".
- FY2020-Q3DroppedAnnual report
「Following termination of the agreement, the rights to the product in North America were returned to our group, and no further development support payments or milestone payments will be made or received between the two companies.」
The North American joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma was mutually terminated effective 13 December 2019, eliminating future payments and receipts of development support payments and milestones under the agreement. - FY2020-Q1RestatedAnnual report
「Against this backdrop, revenue from development support payments and other income received by our group under the joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥189 million for the first quarter of the current consolidated fiscal year, compared with ¥158 million in the same period of the previous year.」
It has been reconfirmed that development support payments and other income under the North American joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma are a source of revenue. - FY2019RestatedAnnual report
「Revenue from development support payments and other income received by our group under the joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥741 million for the current consolidated fiscal year, compared with ¥490 million in the same period of the previous year.」
It has been reconfirmed that development support payments and other income under the North American joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma are a source of revenue. - FY2019-Q3RestatedAnnual report
「Against this backdrop, revenue from development support payments and other income received by our group under the joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥568 million for the first nine months of the current consolidated fiscal year, compared with ¥371 million in the same period of the previous year.」
The revenue structure based on development support payments and other income under the North American joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma has been reconfirmed. - FY2019-Q2RestatedAnnual report
「Against this backdrop, revenue from development support payments and other income received by our group under the joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥415 million for the first six months of the current consolidated fiscal year, compared with ¥249 million in the same period of the previous year.」
The revenue structure based on development support payments and other income received under the North American joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma has been reconfirmed. - FY2018-Q3RestatedAnnual report
「Against this backdrop, revenue from development support payments and other income received by our group under the joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥371 million for the first nine months of the current consolidated fiscal year, compared with ¥758 million in the same period of the previous year.」
The revenue structure based on the North American joint development and sales licensing agreement for SB623 with Dainippon Sumitomo Pharma, including development support payments and other income, has been reconfirmed. - FY2018-Q2RestatedAnnual report
「Against this backdrop, revenue from development support payments and other income received by our group under the joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥249 million for the first six months of the current consolidated fiscal year, compared with ¥684 million in the same period of the previous year.」
It has been reconfirmed that development support payments and other income are being received under the North American joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma. - FY2018-Q1RestatedAnnual report
「Against this backdrop, we received development support payments related to the US Phase IIb clinical trial for chronic-phase cerebral infarction under the joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America.」
It is stated that development support payments related to the US Phase IIb trial for chronic-phase cerebral infarction were received under the joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma. - FY2017RestatedAnnual report
「Under the agreement, going forward, our group and Dainippon Sumitomo Pharma Co., Ltd. will each bear a specified proportion of the development costs for the SB623 cerebral infarction indication in the relevant region, while Dainippon Sumitomo Pharma Co., Ltd. will bear all sales-related costs.」
The framework for the North American joint development and licensing agreement with Dainippon Sumitomo Pharma, including the sharing of development costs and responsibility for sales costs, has been reconfirmed. - FY2017-Q3RestatedAnnual report
「Against this backdrop, revenue from the joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America included US$5 million in milestone revenue received upon enrollment of the first subject in the US Phase IIb clinical trial for chronic-phase cerebral infarction, as well as development support payments and other income. Business revenue for the first nine months of the current consolidated fiscal year was ¥758 million, compared with ¥1,099 million in the same period of the previous year, and operating loss was ¥1,214 million, compared with an operating loss of ¥566 million in the same period of the previous year.」
The joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma and US$5 million in milestone revenue associated with enrollment of the first subject in the Phase IIb trial for chronic-phase cerebral infarction are reiterated. - FY2017-Q2RestatedAnnual report
「Against this backdrop, revenue from the joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. in North America included US$5 million in milestone revenue received upon enrollment of the first subject in the US Phase IIb clinical trial for chronic-phase cerebral infarction, as well as development support payments and other income. Business revenue for the first six months of the current consolidated fiscal year was ¥684 million, compared with ¥411 million in the same period of the previous year.」
The joint development and licensing agreement with Dainippon Sumitomo Pharma and receipt of US$5 million in milestone revenue are reiterated. - FY2017-Q1First statedAnnual report
「Revenue from the North American joint development and licensing agreement for SB623 with Dainippon Sumitomo Pharma Co., Ltd. included milestone revenue of US$5 million, received upon completion of enrollment of the first subject in the US Phase IIb clinical trial for chronic-phase cerebral infarction, as well as development support payments and other income. As a result, business revenue for the first quarter of the current consolidated fiscal year was ¥625 million, compared with ¥284 million in the same quarter of the previous year, and operating income was ¥77 million, compared with an operating loss of ¥81 million in the same quarter of the previous year.」
Under the North American joint development and licensing agreement, US$5 million in milestone revenue was received upon completion of subject enrollment in the Phase IIb trial for chronic-phase cerebral infarction.